english.prescrire.org > Spotlight > 100 most recent > Cerliponase alfa (Brineura°) in neuronal ceroid lipofuscinosis type 2 disease: new data

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Cerliponase alfa (Brineura°) in neuronal ceroid lipofuscinosis type 2 disease: new data

 Marketing Authorisations  In the light of current data, does enzyme replacement therapy with cerliponase alfa enable children with neuronal ceroid lipofuscinosis type 2 (CLN2) disease to lead a life without disabilities? Does it extend survival? And what are its adverse effects?
Full article available for download by subscribers

 ©Prescrire 1 May 2026

Source: "Cerliponase alfa (Brineura°) in neuronal ceroid lipofuscinosis type 2 disease" Prescrire Int 2026; 35 (281): 126-127. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Cerliponase
alfa - Brineura°
and neuronal ceroid
lipofuscinosis type 2"
Prescrire Int 2020;
29 (213): 67.
Subscribers only